Introduction: The rising prevalence of diabetes and its complications, including diabetic nephropathy and obesity, demands innovative therapeutic strategies. PBI-4547, a novel antidiabetic and antifibrotic compound, offers potential benefits in this realm. This study investigates the efficacy and safety of oral PBI-4547 in managing diabetes, diabetic nephropathy, and obesity.
Methods: In this randomized, double-blind, placebo-controlled experiment, 150 patients with T2DM, diabetic nephropathy, and obesity were included. The participants were divided into three groups: low-dose, high-dose, and placebo. The study examined HbA1c, albuminuria, eGFR, and body weight during six months. Safety was assessed through the recording of adverse events.
Results: Significant improvements in glycemic control were observed in both PBI-4547 groups compared to the placebo, with a mean HbA1c reduction of 1.2% in the high-dose group and 0.8% in the low-dose group (p<0.01). Albuminuria decreased by 30% in the high-dose group and 20% in the low-dose group (p<0.05). The high-dose group also exhibited an average weight loss of 5%, and the low-dose group reported moderate but significant weight loss. PBI-4547 was well-tolerated, with no serious adverse events reported.
Conclusion: Oral PBI-4547 significantly improved glycemic control, lessened albuminuria, and induced weight loss in obese T2DM patients, indicating its potential as an all-encompassing diabetes therapy. Further large-scale, long-term studies are needed to verify these outcomes and determine its safety profile.
K.A. Ahmad: None. A.S. Prakash: None. A. Chandra: None. R.K. Jha: None.
